ABBVIE said Health Canada has issued a Notice of Compliance with Conditions for Venclexta (venetoclax). The therapy has been approved for previously treated chronic lymphocytic leukemia patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options. Under NOC/c policy, AbbVie will provide Health Canada with data from additional...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
